Aspirin in Primary Prevention: Current Evidence-Based Approach

Introduction to Aspirin Use

The US Preventive Services Task Force gives a Grade D recommendation (harm outweighs benefit) against initiating aspirin in adults 60 years or older 1
Aspirin should generally NOT be used for primary prevention in most patients with hypertension, hyperlipidemia, or diabetes, as the bleeding risks now equal or exceed the modest cardiovascular benefits in the modern era of optimized risk factor management 1

Patients with a history of gastrointestinal bleeding or peptic ulcer disease should not receive aspirin for primary prevention 2, 1
Concurrent anticoagulation (warfarin, DOACs) is a contraindication for aspirin use in primary prevention 2, 1
Thrombocytopenia or coagulopathy is a contraindication for aspirin use in primary prevention 2, 1
Chronic kidney disease is a contraindication for aspirin use in primary prevention 2, 1
Uncontrolled hypertension is a contraindication for aspirin use in primary prevention 2, 1

The American Diabetes Association states aspirin (75-162 mg/day) "may be considered" for those aged ≥50 years with at least one additional major cardiovascular risk factor (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria) 3, 4
Only in highly select patients aged 40-59 years with ≥10% 10-year ASCVD risk and NO bleeding risk factors should aspirin even be considered, and this is a weak recommendation 2, 1

Use 75-100 mg daily (81 mg in the US) — the lowest effective dose to minimize bleeding complications 2, 1
Doses of 75-162 mg daily are acceptable, but higher doses provide no additional cardiovascular benefit and increase bleeding risk 5, 6, 2

For every 1,000 patients treated for 5 years, aspirin prevents 6 myocardial infarctions but causes 4 major bleeding events 1
Major gastrointestinal bleeding occurs in 2-4 per 1,000 middle-aged adults over 5 years (increasing to 4-12 per 1,000 in older adults) 2, 1
Even low-dose aspirin increases major GI bleeding risk by 60% (relative risk 1.6) 2, 4

Statin therapy has far stronger evidence for cardiovascular risk reduction in primary prevention than aspirin 4
Blood pressure control to <130/80 mmHg per current guidelines 4
Glycemic optimization in diabetic patients (target A1c <7% for most) 4
Smoking cessation, weight management, and regular physical activity 5

Calculate 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equations
Assess for absolute contraindications (age ≥60, bleeding history, anticoagulation, uncontrolled HTN)
If age 40-59 AND ASCVD risk ≥10% AND no bleeding risk factors: engage in shared decision-making discussion 3
Emphasize that bleeding risk approximately equals cardiovascular benefit 1

For patients with established ASCVD (prior MI, stroke, revascularization), aspirin 75-162 mg daily is strongly recommended, as benefits far outweigh risks in this population 3, 2
For aspirin allergy in secondary prevention, substitute clopidogrel 75 mg daily 3, 1

The American Diabetes Association explicitly states aspirin is not recommended for those at low ASCVD risk, such as individuals <50 years with no additional risk factors 7, 8
Patients aged <50 years with no major cardiovascular risk factors have such low baseline risk that bleeding complications outweigh any potential benefit 7, 8

Uncontrolled hypertension is a contraindication for aspirin use 7
Age <21 years is a contraindication for aspirin use due to the risk of Reye syndrome 7

For patients with diabetes aged ≥50 years PLUS at least one additional major risk factor, aspirin 75-162 mg/day "may be considered" after careful discussion of bleeding risks 7, 8, 9

Major gastrointestinal bleeding occurs in 2-4 per 1,000 middle-aged adults over 5 years 10
Even low-dose aspirin increases major GI bleeding risk by 60% (relative risk 1.6) is not supported by this reference, however, hemorrhagic stroke risk increases by 0-2 per 1,000 persons over 5 years 10

The ASCEND trial (2018) in 15,480 patients with diabetes showed only a 12% reduction in vascular events, but major bleeding increased significantly from 3.2% to 4.1% 7

Do not prescribe aspirin simply because a patient has one isolated risk factor without calculating actual 10-year ASCVD risk 7
Do not use higher doses thinking they provide better protection — doses >100 mg increase bleeding without additional cardiovascular benefit 7
Do not confuse primary prevention with secondary prevention — aspirin remains strongly indicated for patients with established ASCVD 7, 8, 9